MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-19-0005881
Ideal Cures Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹239.81 Cr
▲ 6% YoY
Net profit · FY 2025
₹85.77 Cr
Net margin 35.8%
EBITDA · FY 2025
₹106.81 Cr
EBITDA margin 44.5%
Authorised capital
₹10.1 Cr
Registered with MCA
Paid-up capital
₹7.5 Cr
Issued & subscribed
Satisfied charges
₹6.25 Cr
No open charges
Company age
38 yrs
Est. 1988
Employees · EPFO
241
Provident fund records
About Ideal Cures Private Limited
Data last updated:
Ideal Cures Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 July 1988 and has been in existence for over 38 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1988PTC048150. Its GSTIN is 27AAACI1933M1ZH (Maharashtra). The company holds 5 GST registrations, all of them active.
The company has an authorised share capital of ₹10.1 Cr and a paid-up capital of ₹7.5 Cr. It is led by directors Maulek Jawaharlal Desai (Managing Director) and Anita Shekhar Dhande.
Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A/223 – A/229 2nd Flr Virwani Industr Western Express Highway Goregaon (East), Mumbai, Maharashtra, India – 400063.
As per the financials filed for FY 2025, the company reported a revenue of ₹239.81 Cr, a growth of 6% compared to the previous year. For the same year it recorded a net profit of ₹85.77 Cr (net margin 35.8%) and EBITDA of ₹106.81 Cr (EBITDA margin 44.5%). Revenue has grown at a compounded annual rate (CAGR) of 10% over five years.
The company has about 241 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Ideal Cures. As per MCA filings, the company has satisfied charges of ₹6.25 Cr on record. Court records list 11 cases involving the company, including 8 filed by the company and 3 filed against it. The company has 13 deals on record (11 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹20 Lakh; the latest was in March 2023. Its 5 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 2 smaller; the largest is Vivek Pharmachem (India) Limited with revenue of ₹245.53 Cr. The company has 19 MSME Form 1 returns on record between 2016 and 2024, listing 210 overdue payments to 43 micro and small suppliers.
Ideal Cures Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0005881). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website idealcures.com.
Company details
CIN U24239MH1988PTC048150
Registration Number 048150
Incorporation Date 18 July 1988
ROC Mumbai
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0005881
Key People
Maulek Jawaharlal Desai Managing Director Dinesh Laxminarayan Pandey Company Secretary Anita Shekhar Dhande Additional Director Recognitions & Rankings of Ideal Cures
Contact details
Ideal Cures Private Limited's registered office is in Mumbai, Maharashtra. Its website is idealcures.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA/223 – A/229 2nd Flr Virwani Industr Western Express Highway Goregaon (East), Mumbai, Maharashtra, India – 400063
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Ideal Cures Private Limited, buy the company report.
Comprehensive company report
Ideal Cures Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Ideal Cures operates one associated brand: Ideal Cures. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical excipients and coatings systems for solid oral dosage forms | idealcures.com |
Business activity
The main business activity of Ideal Cures is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Ideal Cures Private Limited, buy the company report.
Financials of Ideal Cures Private Limited
FY 2025 filings availableIdeal Cures Private Limited reported revenue of ₹239.81 Cr (up 6% YoY) for FY 2025.
Revenue · FY 2025
₹239.81 Cr ▲ 6%
Net profit · FY 2025
₹85.77 Cr margin 35.8%
EBITDA · FY 2025
₹106.81 Cr margin 44.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 6%
5 years · compounded
▲ 10%
EBITDA CAGR growth
1 year
▲ 8%
5 years · compounded
▲ 15%
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 6% growth in the latest year. EBITDA rose 8% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹106.81 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹85.77 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 44.5% | ||||
| Net Profit Margin | 35.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Ideal Cures Private Limited, buy the company report.
Board of directors and KMP of Ideal Cures Private Limited
Ideal Cures Private Limited currently reports 2 directors and 1 key managerial person. 15 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Maulek Jawaharlal Desai | Managing Director | 01 Apr 2024 | 2 Years 7 Months | Current |
| Dinesh Laxminarayan Pandey | Company Secretary | 01 Nov 2016 | 10 Years 0 Months | Current |
| Anita Shekhar Dhande Also directs: Colorcon Asia Private Limited | Additional Director | 29 Aug 2025 | 1 Years 2 Months | Current |
Peer comparison
Ideal Cures Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vivek Pharmachem (India) Limited | ₹245.53 Cr (FY 2025) | -8.0% | Jaipur, Rajasthan, India | |||
| Blue Circle Organics Private Limited | ₹243.24 Cr (FY 2019) | 35.0% | Mumbai, Maharashtra, India | |||
| Khandelwal Laboratories Private Limited | ₹240.41 Cr (FY 2025) | 2.0% | Mumbai, Maharashtra, India | |||
| Ideal Cures Private Limitedthis company | ₹239.81 Cr (FY 2025) | ₹85.77 Cr | 35.8% | 6.0% | Mumbai, Maharashtra, India | |
| Healthcaps India Limited | ₹239.43 Cr (FY 2025) | -2.0% | Fatehpur, Punjab, India | |||
| Kemwell Biopharma Private Limited | ₹239.14 Cr (FY 2025) | 10.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Ideal Cures Private Limited, buy the company report.
Auditor
Ideal Cures Private Limited is audited by SRBC & Co LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SRBC & Co LLP | FY 2025 | 324982E/E300003 |
Shareholding
The shareholding of Ideal Cures Private Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Ideal Cures Private Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹6.25 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Jun 2010 | 10235235 | Hdfc Bank Limited | ₹6.25 Cr | Satisfied |
To see the full charge records of Ideal Cures Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Ideal Cures Private Limited has 13 deals on record (11 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹20 Lakh; the latest was in March 2023.
Total deals
13
Secondary share transfers
11
Funding round
1
Acquisition
1
Disclosed funding
₹20 Lakh
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: TA Associates, 3 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: Bpsi Holdings LLC, an individual Seller: TA Associates, Suresh Pareek (HUF), 2 individuals |
| Oct 2021 | Acquisition | Undisclosed | Buyer: Colorcon Inc |
| Mar 2017 | Secondary share transfer | Undisclosed | Buyer: TA Associates, an individual Seller: Roha Dye Chem Private Limited , 3 individuals |
| Sep 2016 | Secondary share transfer | Undisclosed | Seller: RS Global Infotech LLP |
To see the full deal history of Ideal Cures Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Ideal Cures Private Limited has 11 court cases on record: 8 filed by Ideal Cures, 3 filed against it. All cases are disposed.
Total cases
11
Filed by the company
8
Filed against the company
3
Disposed
11
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 2 | 0 |
| District courts | 5 | 1 | 0 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons Private cases SS) | Filed by the company against Mission Vivacare Limited and Others and 1 other | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed by the company against M S Saphire Lifesciences Pvt Ltd | Disposed |
| Bombay High Court | Court case (SS) | Filed by the company against M/S. Saphire Lifesciences Pvt. Ltd. | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Ss casess) | Filed against the company by Mumbai Municipal Corporation P-South Ward | Disposed |
| High Court, MAHARASHTRA | Writ petition | Filed by the company against State of Maharashtra Thru the Secretary, Urban Development Dept. and Anr | Disposed |
To see the full case history of Ideal Cures Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Ideal Cures Private Limited has 19 MSME Form 1 returns on record between 2016 and 2024, listing 210 overdue payments to 43 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 43)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Mediraw Pharma & Nutra Private Limited | |||
| Koel Colours Pvt Ltd | |||
| R.P. Products Pharma Equipments Pvt. Ltd. | |||
| Ratnadeep NX | |||
| an individual supplier |
To see the full MSME payment records of Ideal Cures Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Ideal Cures has 5 GST registrations: 5 active. The first 4 active GSTINs are listed below.
Total GSTINs
5
Active
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACI1933M1ZH | Maharashtra | Active | 01 Jul 2017 |
| 27AAACI1933M2ZG | Maharashtra | Active | 01 Apr 2025 |
| 24AAACI1933M1ZN | Gujarat | Active | 01 Jul 2017 |
| 01AAACI1933M1ZV | Jammu and Kashmir | Active | 08 Jul 2017 |
To see the full GST registrations and return filing status of Ideal Cures Private Limited, buy the company report.
Recent activity
Ideal Cures Private Limited has 20 board changes on record since 2016: 5 appointments and 15 cessations. The latest: Anita Shekhar Dhande was appointed as Additional Director on 29 Aug 2025.
AGM
Ideal Cures Private Limited last Annual general meeting of members was held on 23 Sep 2025 as per latest MCA records.
Appointed
Anita Shekhar Dhande was appointed as Additional Director.
Filing
Ideal Cures Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Ceased
David Francis Bain ceased to be Additional Director.
Appointed
Maulek Jawaharlal Desai was appointed as Managing Director.
Ceased
Maulek Jawaharlal Desai ceased to be Additional Director.
Ceased
Dinesh Laxminarayan Pandey ceased to be Additional Director.
Ceased
Sanjay Singh Negi ceased to be Additional Director.
Ceased
Dinesh Kumar Pareek ceased to be Director.
Ceased
Ganesh Bhaskar Gokhale ceased to be Director.
Appointed
Sanjay Singh Negi was appointed as Director.
Ceased
Vaishali Manish Tawde ceased to be Additional Director.
13 earlier events are in the company report.
Frequently asked questions
Ideal Cures is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 July 1988 (38+ years old) and is registered under CIN U24239MH1988PTC048150.
Ideal Cures has 3 current directors and KMP:
- Maulek Jawaharlal Desai - Managing Director
- Anita Shekhar Dhande - Additional Director
- Dinesh Laxminarayan Pandey - Company Secretary
The latest financial statements of Ideal Cures on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Ideal Cures is 27AAACI1933M1ZH, registered in Maharashtra. The company has 5 GST registrations in all, of which 5 are active. Other active GSTINs include 27AAACI1933M2ZG (Maharashtra), 24AAACI1933M1ZN (Gujarat), 01AAACI1933M1ZV (Jammu and Kashmir).
The CIN (Corporate Identification Number) of Ideal Cures is U24239MH1988PTC048150. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ideal Cures has 11 court cases on record: 8 filed by the company and 3 filed against it. Most are in the high courts.
Ideal Cures was incorporated on 18 July 1988, making it 38+ years old. It is registered with the Registrar of Companies, Mumbai.
Ideal Cures has 13 deals on record (11 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹20 Lakh; the latest was in March 2023.
The peers of Ideal Cures by revenue are Vivek Pharmachem (India) Limited, Blue Circle Organics Private Limited, Khandelwal Laboratories Private Limited, Healthcaps India Limited, Kemwell Biopharma Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anita Shekhar Dhande was appointed as Additional Director on 29 Aug 2025. David Francis Bain ceased to be Additional Director on 29 Sep 2024. Maulek Jawaharlal Desai was appointed as Managing Director on 01 Apr 2024. Ideal Cures has 20 board changes on record in total.
Yes, Ideal Cures is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0005881).
Ideal Cures has 19 MSME Form 1 returns on record between 2016 and 2024, listing 210 overdue payments to 43 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages